Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$887.0K
Current Assets
2024 Q2
Current Liabilities
2024 Q2
Current Ratio
2024 Q2
4.91%
Total Assets
2024 Q2
Total Liabilities
2024 Q2
Book Value
2024 Q2
-$1.625M
Cash
2024 Q2
P/E
Last 4 Quarters
N/A
Free Cash Flow
Last 4 Quarters
N/A

Stock Price

Loading...
Market Cap: $124.11 Thousand

About GlobeStar Therapeutics Corp

GlobeStar Therapeutics Corp. is a clinical stage biotechnology company, which engages in the manufacture and patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is headquartered in Richland, Washington. The company went IPO on 2011-05-21. The firm is focused on introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The firm owns the global license from the inventors, who are based in Italy.

Industry: Pharmaceutical Preparations Peers: ACTAVIA LIFE SCIENCES, INC. Allena Pharmaceuticals, Inc. GridAI Technologies Corp International Stem Cell Corp Innoveren Scientific, Inc. NovAccess Global Inc. PREMIER BIOMEDICAL INC

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support